Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Trodelvy has already crossed the blockbuster threshold for Gilead, with sales rising 24% to $1.3 billion last year, although, Gilead's attempts to extend its use into other cancers have had mixed ...

In Trodelvy's favour is that the outlook for patients with HR+/HER2- breast cancer who have progressed despite earlier hormonal therapies, CDK4/6 inhibitors and multiple lines of chemo is pretty ...

Erika Hamilton, MD, shares key insights from the 2025 ASCO Annual Meeting that are set to impact breast cancer treatment.

Up to $1.25 billion ($250 million upfront) of synthetic royalty funding and up to $750 million in secured debt ; Innovative partnership enables Revolution Medicines to retain control over pipeline ...

Interim results from the Phase 2 JAVELIN Bladder Medley trial will be presented, focusing on the efficacy of BAVENCIO in combination with the anti-Trop-2 ADC sacituzumab govitecan (Trodelvy ...

The study revealed that 25 out of 37 hormone receptor-positive patients had a median overall survival of 17.3 months, surpassing the 14.4 months with TRODELVY®. BriaCell’s ongoing Phase 3 study ...